Elizabeth G. O'Farrell
Elizabeth G. O'Farrell's purchase track record
Elizabeth G. O'Farrell has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/24/2023 | GERN | $30K | -14.7% | -14.7% | +16.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
Transaction History
| LNSR | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 | View on chart |
| LNSR | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 | View on chart |
| LNSR | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 | View on chart |
| GERN | ▲ Buy | Open Market | 6,607 | $15K | 8/24/2023 | View on chart |
| GERN | ▲ Buy | Open Market | 6,579 | $15K | 8/24/2023 | View on chart |
| LNSR | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 | View on chart |
| LNSR | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target
Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.